芬吗通周期治疗和连续治疗卵巢早衰的比较研究  

Comparative Study of Femoston Cycle Treatment and Continuous Treatment of Premature Ovarian Failure

作　　者：梁之鹏 宁林莹[1] LIANG Zhipeng;NING Linying(Xinyi City People’s Hospital,Xinyi 525300,China;不详)

机构地区：[1]信宜市人民医院,广东信宜525300

出　　处：《中外医学研究》2021年第16期49-52,共4页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：目的:探讨芬吗通周期治疗和连续治疗卵巢早衰的临床效果与安全性。方法:以2017年1月-2019年12月笔者所在医院妇科门诊诊治的80例卵巢早衰患者为研究对象,全部患者均以芬吗通进行治疗,随机分为两组。A组40例,予以芬吗通周期治疗,患者初始连续用药28 d;如未来月经,患者停药7 d后重复用药,如来月经,患者于月经第5天开始重复用药。B组40例,予以芬吗通连续治疗。比较两组治疗效果。结果:两组治疗3、6个月后FSH与LH均较治疗前下降(P<0.05),E_(2)升高(P<0.05),且治疗6个月后的FSH、LH水平较3个月时更低(P<0.05),E_(2)较3个月时更高(P<0.05),但两组间比较差异无统计学意义(P>0.05)。两组临床治疗有效率比较差异无统计学意义(P>0.05)。A组不良反应发生率(5.0%)低于B组,B组治疗后子宫内膜厚度(10.15±1.35)mm较A组厚,差异均有统计学意义(P<0.05)。结论:芬吗通周期治疗与连续治疗卵巢早衰均可以较好地改善患者临床症状及性激素、血脂水平,其中,周期用药的不良反应发生率低于连续用药,而连续用药对子宫内膜的改善作用更好,在恢复月经和增加经量方面更有优势。Objective:To explore the clinical efficacy and safety of Femoston cycle therapy and continuous therapy for premature ovarian failure.Method:From January 2017 to December 2019,80 patients with premature ovarian failure were randomly divided into two groups.All patients were treated with Femoston.In group A,40 patients were treated with Femoston for 28 days,the patients with future menstruation stopped taking the medicine for 7 days and then repeated the drug,the patients with coming menstruation began to take the medicine again on the 5th day of menstrual cycle.In group B,40 patients were treated continuously with Femoston.The effect was compared between the two groups.Result:After 3 and 6 months of treatment,FSH and LH of the two groups were lower than before treatment(P<0.05),and E_(2) was increased(P<0.05).The levels of FSH and LH after 6 months of treatment were lower than those of 3 months after treatment(P<0.05),and E_(2) was higher than that of 3 months after treatment(P<0.05).But the difference between the two groups was not statistically significant(P>0.05).And no significant difference in clinical efficacy between the two groups(P>0.05).The side effect rate(5.0%)in group A was lower than that in group B,and the endometrial thickness(10.15±1.35)mm in group B was thicker than that in group A after treatment(P<0.05).Conclusion:Both periodic and continuous Femoston treatments can better improve the clinical symptoms and levels of sex hormones and blood lipids in patients with premature ovarian failure,and the incidence of adverse reactions of Femoston is lower than that of continuous treatment.However,continuous use of medicine on the endometrium to improve the role of better in the recovery of menstruation and increase the volume of menstruation is more advantageous.

关 键 词：卵巢早衰 芬吗通 周期治疗 连续治疗 疗效 安全性 

分 类 号：R711.75[医药卫生—妇产科学]